Please assess the completion status of the following clinical trial:

Trial Title: Detection of PitNET Tissue During TSS Using Bevacizumab-800CW

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with an established diagnosis of PitNET with a Knosp grade of 3 or 4 who are scheduled to undergo TSS.~* WHO performance status 0-2~* Signed written informed consent~Exclusion Criteria:~* Medical or psychiatric conditions that compromise the patient's ability to give informed consent~* Pregnant or lactating women. Documentation of a negative pregnancy test must be available for woman of childbearing potential. Woman of childbearing potential are pre- menopausal women with intact reproductive organs and women less than two years after menopause~* History of infusion reactions to bevacizumab or other monoclonal antibody therapies.~* Inadequately controlled hypertension with or without current antihypertensive medication~* Within 6 months prior to inclusion: myocardial infarction, TIA, CVA, pulmonary embolism, uncontrolled chronic hepatic failure, unstable angina pectoris

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NIR endoscopic TSS with 4.5 mg bevacizumab-800CW (Type: EXPERIMENTAL): IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
- NIR endoscopic TSS with 10 mg bevacizumab-800CW (Type: EXPERIMENTAL): IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
- NIR endoscopic TSS with 25 mg bevacizumab-800CW (Type: EXPERIMENTAL): IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).